Clinical lung cancer最新文献

{"title":"Histologic Transformation of ALK-Rearranged Lung Adenocarcinomas to High-Grade LCNEC: Clinical and Molecular Description of Three Cases.","authors":"Paolo Ambrosini, Daniela Miliziano, Giorgia Di Liberti, Daniele Lorenzini, Silvia Marchesi, Anna Bassetti, Elena Tamborini, Rita Leporati, Teresa Beninato, Laura Mazzeo, Marta Brambilla, Monica Ganzinelli, Arsela Prelaj, Claudia Proto, Filippo Guglielmo De Braud, Giuseppe Lo Russo, Mario Occhipinti","doi":"10.1016/j.cllc.2024.11.012","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.11.012","url":null,"abstract":"","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Lung Biomarker Testing on Out-Of-Pocket Costs for Metastatic Non-Small-Cell Lung Cancer.","authors":"Laila A Gharzai, Sarah Bell, Divya M Gupta, Ruth C Carlos","doi":"10.1016/j.cllc.2024.11.011","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.11.011","url":null,"abstract":"<p><strong>Background: </strong>Biomarker testing in metastatic non-small lung cancer (NSCLC) is critical for appropriate treatment. Claims-based datasets offer real-world information on the use and cost of biomarker testing.</p><p><strong>Materials and methods: </strong>We used 2013-2021 data from Optum's de-identified Clinformatics Data Mart Database. Eligible patients were adults with ≥ 2 NSCLC diagnosis codes and ≥ 2 claims of a secondary malignant neoplasm. We excluded patients with another primary or no continuous insurance coverage 12 months prior and 6 months after diagnosis. We assessed out-of-pocket (OOP) costs. Descriptive statistics were used to assess testing rates, and multivariable analyses (MVA) were performed to assess factors associated with testing.</p><p><strong>Results: </strong>We identified 4377 patients with metastatic NSCLC (mean age 60 years (SD 8.33), 49.6% female, 76.7% former smokers). Testing rates within 2 months of diagnosis increased from 58.15% in 2013 to 69.96% in 2021. On MVA, biomarker testing was associated with younger age, nonsmokers, Mountain geographic region, and point-of-service insurance plans. Biomarker testing was associated with a median OOP cost of $98 (IQR: $43.87-$306.58). Patients who underwent biomarker testing had a median total OOP cost of all services within 6 months of diagnosis of $3560.20 (IQR: $1538.37-$6199.44) compared to $1979.58 (IQR: $725.75-$4003.06) for those who did not undergo biomarker testing.</p><p><strong>Conclusions: </strong>Using claims data, we find that most patients with metastatic NSCLC undergo biomarker testing early in their treatment course (0-60 days), suggesting that testing is appropriately being obtained early on in their treatment course, but this testing is associated with substantially higher overall OOP costs to patients.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical, Dosimetric and Radiomic Features Predictive of Lung Toxicity After (Chemo)Radiotherapy.","authors":"Cécile Evin, Léo Razakamanantsoa, François Gardavaud, Léa Papillon, Hamza Boulaala, Loïc Ferrer, Olivier Gallinato, Thierry Colin, Sondos Ben Moussa, Yara Harfouch, Jean-Noël Foulquier, Sophie Guillerm, Jean-Emmanuel Bibault, Florence Huguet, Mathilde Wagner, Eleonor Rivin Del Campo","doi":"10.1016/j.cllc.2024.11.003","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.11.003","url":null,"abstract":"<p><strong>Background: </strong>Treatment of locally advanced non small cell lung cancer (LA-NSCLC) is based on (chemo)radiotherapy, which may cause acute lung toxicity: radiation pneumonitis (RP). Its frequency seems to increase by the use of adjuvant durvalumab therapy.</p><p><strong>Aims: </strong>To identify clinical, dosimetric, and radiomic factors associated with grade (G)≥2 RP and build a prediction model based on selected parameters.</p><p><strong>Patients and methods: </strong>This is a retrospective multicenter cohort study including patients receiving radiation therapy between 2015 and 2019 for LA-NSCLC. Baseline computed tomography scanners were segmented to extract radiomic features from the \"Lung - Tumor\" volume. Variables associated with the risk of G≥2 RP in the descriptive analysis were then selected for explanatory analysis, followed by predictive analysis.</p><p><strong>Results: </strong>153 patients were included in 4 centers (51 with G≥2 RP). Factors associated with G≥2 RP included a high initial hemoglobin level, dosimetric factors (mean dose to healthy lungs, lung V20Gy and V13Gy), the addition of maintenance durvalumab, and 7 radiomic features (intensity distribution and texture). Other factors were associated with an increased risk of G≥2 RP in our explanatory model, such as older age, low Tiffeneau ratio, and a decreased initial platelet count. The best-performing predictive model was a random forest-based learning model using clinical, dosimetric, and radiomic variables, with an area under the ROC curve of 0.72 (95%CI [0.63; 0.80]) versus 0.64 for models using one type of data.</p><p><strong>Conclusion: </strong>The addition of radiomic features to clinical and dosimetric ones improves prediction of the occurrence of G≥2 RP in patients receiving radiotherapy for lung cancer.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142821864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lobectomy Is Not Associated With Improved Survival as Compared to Segmentectomy in Early-Stage Lung Cancer Patients With Visceral Pleural Invasion.","authors":"Gregory L Whitehorn, Hamza Rshaidat, Isheeta Madeka, Jonathan Martin, Shale J Mack, Luke Meredith, Sneha Alaparthi, Tyler R Grenda, Nathaniel R Evans, Olugbenga T Okusanya","doi":"10.1016/j.cllc.2024.11.007","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.11.007","url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this study is to utilize a representative national sample to compare survival outcomes of patients with visceral pleural invasion (VPI) who underwent either a lobectomy or a segmentectomy.</p><p><strong>Methods: </strong>National Cancer Database from 2010 to 2019 was utilized. Patients with tumor size ≤ 2 cm, with VPI, non-small cell lung cancer (NSCLC), with a known vital status were included in the study. A propensity match analysis was performed to compare VPI patients undergoing either lobectomy or segmentectomy.</p><p><strong>Results: </strong>Of the 66,181 patients who met the inclusion criteria, 6,575 (9.9%) had VPI. In postmatch analysis, there was no significant difference in 5-year survival in patients whose cancer had VPI and underwent either lobectomy or segmentectomy (76 [77.1%] vs. 71 [65.7%]; P = .23). Patients who underwent lobectomy and had VPI had poorer 5-year survival compared to patients who underwent a lobectomy and did not have VPI (1,154 [73.7%] vs. 1,240 [78.5%]; P < .001). There was no difference in 5-year survival between patients who underwent a segmentectomy and had VPI and patients who underwent a segmentectomy and did not have VPI (71 [65.7%] vs. 79 [71.0%]; P = .36).</p><p><strong>Conclusion: </strong>A lobectomy was not associated with improved survival as compared to patients who underwent a segmentectomy in patients with early-stage NSCLC with VPI. VPI remains a poor prognostic factor for survival regardless of the procedure performed. This data would indicate that the presence of VPI should not be a determining factor in the anatomic lung resection selected in patients with small, early-stage NSCLC.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142821865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transarterial Embolization for the Management of Emergent Hemoptysis in Patients With Primary and Metastatic Lung Tumors.","authors":"Ruben Geevarghese, Elena N Petre, Etay Ziv, Ernesto Santos, Lee Rodriguez, Ken Zhao, Vlasios S Sotirchos, Stephen B Solomon, Erica S Alexander","doi":"10.1016/j.cllc.2024.11.008","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.11.008","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the role of systemic arterial embolization in patients with primary and metastatic lung tumors presenting with hemoptysis requiring emergent management.</p><p><strong>Patients and methods: </strong>This retrospective single-center study evaluated patients undergoing transarterial embolization for emergent hemoptysis. Endpoints included technical success, clinical success and overall survival. Clinical success was divided into partial or complete, and defined as absence (complete) or subtotal (partial) reduction in frequency and/or volume of hemoptysis in the first 24-hours following embolization. Predictive factors for clinical outcomes were evaluated using univariate analysis. Adverse events were graded according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0.</p><p><strong>Results: </strong>Thirty-seven patients were identified, including 21/37 (56.8%) patients with primary lung cancer. Clinical success was achieved in 31/37 (83.8%) patients. Median overall survival was 18 days (95% CI, 10-95). Median hemoptysis-free survival was 270 days (95% CI 7 to not reached). No significant predictors of hemoptysis-free survival were identified. Prior chemotherapy (HR 2.69, 95% CI, 1.08-6.67; P = .03) was associated with poorer overall survival. History of primary lung tumor (vs. metastatic tumor) was associated with improved overall survival (HR 0.45, 95% CI, 0.21-0.95; P = 0.04). No serious adverse events (CTCAE Grade ≥ 3) were found to be directly attributable to the embolization.</p><p><strong>Conclusion: </strong>Hemoptysis requiring emergent management in patients with lung malignancy carries a poor prognosis. Transarterial embolization is feasible, safe and may be an effective management option, although further research is warranted to identify which patients are likely to derive the greatest benefit.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhanced Recovery With Aggressive Ambulation Decreases Length of Stay in Lung Cancer Surgery.","authors":"Ju Ae Park, Duy Pham, Kasper Nilsson, Lolita Ramsey, Diana Morris, Sandeep J Khandhar, Michael J Weyant, Kei Suzuki","doi":"10.1016/j.cllc.2024.11.010","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.11.010","url":null,"abstract":"<p><strong>Objective: </strong>Thoracic Enhanced Recovery with Ambulation after Surgery (T-ERAS) protocol at our institution includes ambulation into the operating room and 250-feet ambulation within 1 hour of extubation. We compared the average length of stay (LOS) between T-ERAS patients and that predicted using a validated surgical risk calculator.</p><p><strong>Methods: </strong>We retrospectively reviewed patients undergoing lung cancer resection with minimally invasive approach from 2012 to 2022. Patients aged ≥ 18 were included if early ambulation was documented. Patient information were entered into the American College of Surgeon's National Surgical Quality Improvement Program Risk Calculator (NSQIP) to obtain the predicted LOS. Descriptive statistics, comparisons of observed versus predicted LOS (O/P ratio), and nonparametric testing were conducted.</p><p><strong>Results: </strong>Of 940 patients reviewed, 886 met eligibility. For the study cohort, average age was 68, and 514 (58.0%) were female. By procedure, there were 631(71.2%) lobectomy, 204 (23.0%) wedge, 26 (2.9%) segmentectomy, 20 (2.3%) bilobectomy, and 5 (0.6%) pneumonectomy. The average LOS observed for the entire cohort was 1.2 days (median 1.0 day) compared to the predicted LOS of 3.4 days with the NSQIP (median 4.0). Overall, 842 (95%) of patients had LOS better than predicted (O/P ratio < 1), 19 (2.1%) had LOS as predicted (O/P ratio = 1), and 25 (2.8%) had LOS longer than predicted (O/P ratio > 1). The mean O/P ratio was 0.34.</p><p><strong>Conclusion: </strong>Average LOS with T-ERAS protocol was 1.2 days compared to the predicted average of 3.6 days in patients undergoing minimally invasive lung cancer resections. Our study provides a potential protocol to shorten the LOS beyond what is predicted by NSQIP.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation Between the Extent of N1 Lymph Node Station Examination and Prognosis in Stage I Non-small Cell Lung Cancer Patients: One Station is Insufficient.","authors":"Junhong Liu, Bingji Cao, ZhiHua Shi, Minglei Song, Junfeng Liu","doi":"10.1016/j.cllc.2024.11.009","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.11.009","url":null,"abstract":"<p><strong>Background: </strong>Examination standards for hilar and intrapulmonary (N1) lymph nodes (LNs) have been debated. The objective of this study was to assess the prognostic significance of the extent of examination for N1 LN stations in patients with pathological stage I non-small cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>A total of 1868 patients were identified and divided into 3 groups on the basis of the number of N1 stations examined: group A (≥3 stations), group B (2 stations) and group C (1 station). Moreover, we investigated the prognostic significance of each individual N1 station examined. The primary outcome was 5-year disease-free survival (DFS).</p><p><strong>Results: </strong>Overall, 1062, 607, and 199 patients were in groups A, B, and C, respectively. The baseline demographic and clinical characteristics were similar among the groups, except for the tumor side. The 5-year DFS rates were comparable between groups A and B (85.1% vs. 82.7%, P = .3), both of which were significantly greater than that of group C (74.4%) (P < .01). Similar results were observed for the corresponding 5-year overall survival rates. The number of N1 stations examined was an independent predictor in multiple analyses. Additionally, the examination of stations 10 and 13 were independent favorable predictors for 5-year DFS.</p><p><strong>Conclusion: </strong>For patients with pathological stage I NSCLC, examination of only 1 N1 station is insufficient. Examinations of a minimum of two N1 stations, including stations 10 and 13, is recommended to obtain the optimal survival benefit.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metrics for Perioperative Exercise in Patients Undergoing Lung Cancer Resection: A Systematic Review.","authors":"Tyler W Stumm, Shady Mina, Olugbenga Okusanya, Scott Cowan, Nathaniel R Evans, Tyler R Grenda","doi":"10.1016/j.cllc.2024.11.006","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.11.006","url":null,"abstract":"<p><p>Perioperative exercise interventions have been shown to mitigate morbidity associated with lung resection. While these interventions have established a role in this patient population, there has been little discussion regarding which metrics are used to standardize perioperative exercise interventions. A better understanding of these metrics is needed to define best practices and ensure interventions are reproducible. A systematic review of the literature was performed using CINAHL, PubMed/MEDLINE, and SCOPUS. The initial review yielded a total of 3456 results. After review of titles and abstracts, 119 studies remained. The included studies underwent detailed review of the manuscript and 29 were found to meet the inclusion criteria for the review. A total of 29 studies were selected for inclusion. Included studies were completed on adult patients with diagnosis of lung cancer who underwent lung resection surgery and participated in a standardized exercise intervention before or after their surgery. The most common metrics used to grade exercise interventions were percent maximal workload (%Wmax) based on preoperative cardiopulmonary exercise testing (CPET), which was used in 41% of included studies, and symptom limited Borg rating of perceived exertion, which was used in 38% of included studies. There was significant variation in metrics used for tracking perioperative exercise interventions. Standardization of validated metrics for perioperative exercise interventions, specifically using percent of maximal workload and the Borg scale, would impact the ability to compare future studies and the effectiveness of exercise interventions.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraoperative Molecular Imaging With Pafolacianine: Histologic Characteristics of Identified Nodules.","authors":"Inderpal S Sarkaria, Timothy G Biro, Sunil Singhal, Rishindra M Reddy, Linda W Martin, David C Rice, Alex S Lopez, Gary Stevens, Tina Barret, Sudish C Murthy","doi":"10.1016/j.cllc.2024.11.004","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.11.004","url":null,"abstract":"<p><strong>Background: </strong>With increased early detection efforts, surgery for early-stage lung cancer is expected to rise. Pafolacianine is the first FDA approved targeted optical imaging agent indicated as an adjunct for intraoperative identification of malignant and nonmalignant pulmonary lesions in adult patients with known or suspected cancer in the lung.</p><p><strong>Methods: </strong>This is a retrospective review of the malignant and nonmalignant lesions identified by pafolacianine with intraoperative molecular imaging (IMI) in the multi-center Phase 2 and Phase 3 ELUCIDATE clinical trials. All lesions meeting the intent to treat criteria from the combined studies were included. Histopathology for malignant and nonmalignant lesions and immunohistochemistry (ICH) for folate receptor alpha (FRα) and folate receptor beta (FRβ), which pafolacianine binds to, were assessed.</p><p><strong>Results: </strong>A total of 273 lesions resected from 191 patients were analyzed. The identification of primary and occult malignant lesions with pafolacianine in combination with standard practice was improved (P < .001) when compared to standard practice alone. A range of histologies were demonstrated including adenocarcinoma (primary and metastatic), squamous cell carcinoma, adenoid cystic carcinoma, chordoma, lymphoma, and papillary thyroid cancer. Ninety-two percent (205 of 223) of lesions tested for folate expression were positive for FRα or FRβ expression.</p><p><strong>Conclusions: </strong>While initially intended to identify adenocarcinoma, IMI with pafolacianine targets a broad histological cross-section of malignant and nonmalignant primary and metastatic lesions in the lung. As real-world use expands, additional insight will continue to inform utility of pafolacianine in clinical practice and may broaden clinical applicability.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Oncogene Driver Mutations with Recurrence and Survival in Stage I Nonsmall Cell Lung Cancer.","authors":"Daniel M Libby, Laura J Libby, Xiaoyue Ma, Jason Chua, Tahj Blow, Peyman Razavi, Ashish Saxena","doi":"10.1016/j.cllc.2024.10.016","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.10.016","url":null,"abstract":"<p><strong>Background: </strong>Stage I nonsmall cell lung cancer (NSCLC) is primarily treated with surgical resection and has a favorable prognosis with an expected recurrence rate of 30%. New methods to risk stratify patients with stage I NSCLC are needed to help select those that might benefit from more active surveillance or adjuvant therapy.</p><p><strong>Methods: </strong>We analyzed clinical data from 1330 patients (1469 tumors) with NSCLC and correlated it with next-generation sequencing (NGS). To reduce the potential confounding variables of stage and treatment, this analysis only included patients with stage I NSCLC in whom surgical resection was the primary treatment.</p><p><strong>Results: </strong>In 570 patients (600 tumors), 75 (12.5%) developed recurrence. Recurrence occurred in 37.5% of patients with KRAS G12V mutation versus 11.1% of patients without this mutation (P < .001). A lower chance of recurrence was associated with \"any EGFR\" mutation (6.74% vs. 14.9%, P = .006). A history of coronary artery disease (CAD) increased the chance of recurrence: OR 2.7 (1.57-4.89, P < .001). Shorter survival was predicted by KRAS G12V (P = .009) and \"other TP53\" mutation (P = .025). KRAS G12V, KRAS G13D, MET E168D, PTEN, and \"other TP53\" were oncogene mutations associated with reduced survival in stage I NSCLC. CAD, type 2 diabetes (DM2), and \"other cancer\" were medical comorbidities associated with reduced survival in stage I NSCLC.</p><p><strong>Conclusions: </strong>Oncogene mutations such as KRAS G12V and EGFR may have implications for cancer surveillance strategies and inform future treatment trials of stage I NSCLC.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142823805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}